Two subsidiaries of Omnicare Specialty Care Group (SCG) recently announced they have been chosen to provide services to idiopathic pulmonary fibrosis (IPF) patients taking OFEV® (nintedanib), a recently-approved tyrosine kinase inhibitor developed by Boehringer Ingelheim. RxCrossroads and Advanced Care Scripts (ACS) have been selected to carry out reimbursement and other support services for patients, caregivers, and healthcare providers who are prescribing or being prescribed the drug. Additionally, ACS will be responsible for a portion of the limited distribution specialty pharmacy network, which includes clinical support and nationwide product dispensing.
“Omnicare SCG is pleased to support this effective treatment option,” said Nitin Sahney, Chief Executive Officer of Omnicare. “Through our partnership with Boehringer Ingelheim and support of OFEV, we are proud to have the opportunity to support the thousands of patients living with this unfortunate disease and provide solutions for their current unmet need.”
It was only recently that OFEV received final marketing approval from the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF), which is estimated to affect 132,000 Americans. IPF is a rare, fast-progressing, fatal pulmonary disorder that causes spontaneous scarring of the lungs, leading to a debilitating decrease in lung function until death in 3-5 years. OFEV is the first of its kind drug indicated for IPF.
RxCrossroads specializes in brand support services and advancement of affiliated programs, wherein case management teams aid patients in filing for and claiming healthcare reimbursement. The company’s specialists are skilled in payer coverage, coding, reimbursement concerns, appeals and authorization support, as well as product distribution. Additionally, they design and conduct clinical programs geared towards backing products and their targeted patient populations. They are continuously working on building and enhancing collaborative partnerships for highly customizable programs that cater uniquely to each brand they handle.
Meanwhile, ACS specializes in the management and dispensing of a wide array of disease-specific pharmacologic treatments, and providing care to patients with serious respiratory ailments.
In other news for the drug OFEV®, a recent Bloomberg report revealed a year’s worth of treatment would cost an IPF patient a staggering $96,000. Its competitor, Esbriet (pirfenidone) by InterMune is only slightly less pricey at $94,000 a year.